MAP Series: Quad Medison County Mother’s HPV & mRNA Vaccine Treatment Announcement

Researcher quad Medison Co.,Ltd.

Quadmedicine unveils a next-generation microneedle delivery platform, ‘MAP series,’ targeting global pharmaceutical needs with painless self-administration technology.

Microneedle Tech Promises Painless Drug delivery for Hair Loss and Vaccines

In a significant leap beyond customary injections, a new microneedle delivery platform, dubbed the ‘MAP series,’ is making waves. This technology, developed by Quadmedicine, offers a groundbreaking approach to drug and vaccine delivery, promising painless self-administration and enhanced efficacy. The innovation is detailed across multiple international journal publications, highlighting it’s potential to revolutionize patient care.

The ‘MAP series’ platform utilizes fine, acupuncture-like biomaterials to meet the core needs of the global pharmaceutical industry.it allows for self-administration without the discomfort often associated with needles. This positions it as a key player in advancing medical treatments worldwide.

S-MAP Targets Autoimmune Diseases and Hair Loss

The first platform in the series, S-MAP (Separable MicroneEdle Array Platform), is designed for the safe delivery of JAK inhibitors. Previously administered orally, these drugs raised concerns about systemic side effects. S-MAP, however, selectively delivers the inhibitors to the target site via a hyaluronic acid-based microneedle structure. This targeted approach has shown a notable 2.6-fold improvement in hair regeneration for circular hair loss.

Beyond hair loss, S-MAP shows promise for conditions like psoriasis and atopy. Its ability to provide sustainable release makes it an attractive option for joint advancement with global pharmaceutical companies seeking localized JAK inhibitor strategies. This research was published in Carbohydrate Polymers.

D-MAP Enhances Vaccine Delivery, Bypassing Cold Chain

D-MAP (Disolvable MicroneEdle Array Platform) focuses on stabilizing virus-like particles (vlps) for vaccines. It efficiently induces an immune response through the oral mucosa.The technology leverages the rapid absorption properties of mucosal tissue to stimulate both local and systemic immunity, fostering long-term immune memory.

Crucially, D-MAP does not require refrigerated storage. This makes it ideal for regions with limited cold chain infrastructure, aligning with global health initiatives from organizations like the Gates Foundation, GAVI, and WHO for widespread HPV vaccine distribution. Microneedle-based vaccine delivery is recognized as a vital global innovation. This study appeared in Advanced Healthcare Materials.

D-MAP’s capabilities position it as an optimized platform for collaboration with global vaccine partners.

P-MAP Stabilizes mRNA Formulations for Easy Distribution

The third platform, P-MAP (Preservable MicroneEdle Array Platform), addresses the stability of mRNA-LNP formulations. It solidifies and efficiently delivers these complex formulations within the body. P-MAP ensures stability at room temperature, allowing for long-term distribution without refrigeration.

This feature is particularly valuable for rapid deployment and self-administration systems during public health crises, such as pandemics. P-MAP is seen as a strategic technology for building swift distribution networks.

Quadmedicine is currently engaged in joint research and development with global pharmaceutical companies. The ‘MAP series’ is expected to be integrated into next-generation mRNA vaccines and treatment pipelines. This signifies a strategic shift toward platform-based development, fostering global partnerships. The findings are slated for publication in the European Journal of Pharmaceutics and Biopharmaceutics.

“All of these studies are based on the premise of technology commercialization,” a statement from the company indicated.